Tue, Jun 23 · 8:00

At the PREDiCT: Imaging Modalities for Oncology Drug Development Summit we will reveal the strategy behind the multimodal applications to understand how this information can determine clinical candidate success.

Join us in Boston with 60+ experts alongside organisations such as National Institute of Health, Genentech, MD Anderson Cancer Institute, Bristol Myers Squibb and more and utilize industry insight behind the latest imaging modalities to monitor immune responses in a safe and non-invasive manner, enabling you to accelerate your oncology drug development with confidence.

Oncology drug developers face a challenge to quickly understand drug targeted response to deliver safe products to patients. Effectively incorporating imaging is instrumental to improve understanding of the complex interactions between tumor and the immune system, lowering downstream risk of candidate failure.

The PREDiCT: Imaging Modalities for Oncology Drug Development Summit, June 23-25, Boston MA, will be the pioneering platform across preclinical and clinical stages to guide your application of multimodal imaging to enhance therapeutic success. Bringing together 60+ imaging experts from drug developers and leading academics across 3 days we will provide you with leading strategic applications behind targeted drug response to fast-track your clinical oncology pipeline.

Brochure: https://go.evvnt.com/616469-2?pid=5731

Industry - Conference + 3 Workshops: USD 3546.0,
Industry - Conference + 2 Workshops: USD 3197.0,
Industry - Conference + 1 Workshop: USD 2848.0,
Industry - Conference Only: USD 2499.0,
Industry - Workshop Only: USD 449.0,
Academic - Conference + 3 Workshops: USD 2846.0,
Academic - Conference + 2 Workshops: USD 2597.0,
Academic - Conference + 1 Workshop: USD 2348.0,
Academic - Conference Only: USD 2099.0,
Academic - Workshop Only: USD 349.0

Speakers: Alexander Savchenko, IHC/ISH and Digital Pathology Diagnostic Group Director, Novartis, Martin J Schnermann, Investigator, National Cancer Institute, Mohan Singh, Investigator: Imaging Mass Cytometry GlaxoSmithKline, Mark Pagel, Professor, Department of Cancer Systems Imaging Department of Cancer Systems Imaging, Division of Diagnostic Imaging, MD Anderson Cancer Center, Cleopatra Kozlowski, Senior Scientist, Genentech, James Basilion, Director, Case Center for Imaging Research, Case Western Reserve University, John Waterton, Professor - Translational Imaging, University of Manchester, Mohammad Rashidian, Member of the Faculty, Dana-Farber Cancer Institute, Alexander Adler, Scientist, Regeneron Pharmaceuticals, Mike Farwell, Assistant Professor, University of Pennsylvania, Peter Choyke, Program Director Molecular Imaging, NCI, Khalid Shah Vice Chair of Research, Brigham and Women's Hospital Director, Center for Stem Cell Therapeutics and Imaging Brigham And Women's Hospital, Gabriela Kramer-Marek, Team Leader, Preclinical Molecular Imaging, Institute of Cancer Research, David Leung Director - Oncology Imaging And Medical Medical, Oncology Imaging, Exploratory Clinical And Translational Research Bristol-Myers Squibb, Vaishali Shinde Principal Scientist - Clinical Biomarker Innovation And Development, Quantitative Translational Sciences Takeda, Xiaoyou Ying Director And Head of Bioimaging, Translational In vivo Models And Global Research Platform And Research And Development Sanofi, Chaitanya Divgi CEO Divgi Consulting Inc.